Transplant trial halted: diabetes drug tested for organ protection
NCT ID NCT04906213
Summary
This study tested whether empagliflozin, a medication for type 2 diabetes, could help protect the heart and kidneys in people who received a kidney transplant. It involved 20 transplant recipients, some with diabetes and some without, who took either the drug or a placebo for 18 months. The trial was terminated early, and researchers measured changes in kidney function, heart structure, and infection rates.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.